Strategies for Reducing the PGM Loading in High Power AEMFC Anodes

Anion Exchange Membrane Fuel Cells (AEMFCs) have experienced a significant rise in attention in recent years, largely motivated by the potential to overcome the costs that have plateaued for proton exchange membrane fuel cells. However, despite significant advances in power generation, membrane conductivity, membrane stability, and catalyst activity, the vast majority of high performing AEMFCs are fabricated with a high PGM loading (0.4–0.8 mg cm−2). This work demonstrates an electrode fabrication method that reduces the anode catalyst loading by 85% while still achieving performance ca. 1 W cm−2 – accomplished by designing a multi-layered electrode comprised of an optimized ionomer:carbon:PGM ratio catalyst layer coupled with a hydrophobic microporous layer. If paired with a high-performing PGM-free cathode, this new anode shows the potential to meet existing DOE PGM loading and performance targets

Developing a generic business case for an advanced chronic liver disease support service

INTRODUCTION: Liver disease deaths are rising, but specialist palliative care services for hepatology are limited. Expansion across the NHS is required. METHODS: We surveyed clinicians, patients and carers to design an 'ideal' service. Using standard NHS tariffs, we calculated the cost of this service. In hospitals where specialist palliative care was available for liver disease, patient-level costs and bed utilisation in last year of life (LYOL) were compared between those seen by specialist palliative care before death and those not. RESULTS: The 'ideal' service was described. Costs were calculated as whole time equivalent for a minimal service, which could be scaled up. From a hospital with an existing service, patients seen by specialist palliative care had associated costs of £14 728 in LYOL, compared with £18 558 for those dying without. Savings more than balanced the costs of introducing the service. Average bed days per patient in LYOL were reduced (19.4 vs 25.7) also intensive care unit bed days (1.1 vs 1.8). Despite this, time from first admission in LYOL to death was similar in both groups (6 months for the specialist palliative care group vs 5 for those not referred). CONCLUSIONS: We have produced a template business case for an 'ideal' advanced liver disease support service, which self-funds and saves many bed days. The model can be easily adapted for local use in other trusts. We describe the methodology for calculating patient-level costs and the required service size. We present a financially compelling argument to expand a service to meet a growing need.Published version (12 month embargo), accepted version (12 month embargo)RD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted